CREKA-modified nanoplatform demonstrates targeted thrombolysis and excellent hemocompatibility in vitro for retinal diseases.

Retinal thrombotic diseases are a leading cause of vision impairment, yet current treatments often fail to directly resolve the underlying vascular occlusion. Existing thrombolytic therapies can carry significant risks of systemic bleeding due to their non-specific action. There is an urgent need for targeted delivery systems that can precisely deliver therapeutic agents to the clot site, minimizing off-target effects. This study addresses this gap by developing a multifunctional nanoplatform designed for specific clot targeting and enhanced safety in the delicate retinal vasculature.

Researchers developed a novel PLGA-PFP-rtPA nanoparticle system, specifically modified with the CREKA peptide for targeted delivery. This nanoplatform was designed for thrombolysis, aiming to resolve vascular occlusion in retinal thrombotic diseases. The study conducted comprehensive in vitro characterization, focusing on both efficacy (as stated in the title) and, critically, hemocompatibility. Evaluations included hemolysis assays, assessment of coagulation function, complement activation (measuring C3a levels), and platelet activation across a therapeutically relevant concentration range up to 800 µg/mL.

The comprehensive in vitro hemocompatibility evaluations revealed highly encouraging results for the CREKA-modified nanoplatform. > No adverse effects were observed across all tested parameters within the therapeutically relevant concentration range, specifically up to 800 µg/mL. This included a complete absence of hemolysis, indicating the nanoplatform's safety for red blood cells. Furthermore, the system maintained normal coagulation function, suggesting it does not interfere with the body's natural clotting mechanisms outside the target thrombus. Crucially, there was no detectable complement activation, as evidenced by stable C3a levels, which is vital for avoiding systemic inflammatory responses. Similarly, the nanoplatform did not induce platelet activation, minimizing the risk of unintended thrombotic events. While the abstract snippet primarily detailed these robust biocompatibility findings, the platform was designed for targeted thrombolysis, with its efficacy also characterized in the study, though specific quantitative results for thrombolytic efficacy were not provided in this abstract excerpt.